The national system for anticoagulant control depends on drawing the best line obtained by visual comparison of the points representing corresponding prothrombin ratios with the British comparative thromboplastin in the local reagent. This line is then used to correct subsequent values using the local laboratory method of corresponding values in terms of the British comparative thromboplastin.
SYNOPSIS
The national system for anticoagulant control depends on drawing the best line obtained by visual comparison of the points representing corresponding prothrombin ratios with the British comparative thromboplastin in the local reagent. This line is then used to correct subsequent values using the local laboratory method of corresponding values in terms of the British comparative thromboplastin.
A study has been made of the statistical validity of the recommended system for anticoagulant control using the Quick one-stage test by comparing the line drawn by inspection with the confidence limits of the regression line.
There was little difference between the best straight line by visual comparison and the calculated line for the majority of hospitals. The recommended procedure, therefore, provides an adequate conversion of the local method to the British comparative thromboplastin without the need for calculation.
The significance of aberrant points is discussed and it is suggested that when more than two of the 12 results fall in this category the standardization procedure should be repeated.
A national scheme for anticoagulant control has been introduced recently by the British Committee for Standards in Haematology. This is based on two principles: (1) the use of a* single tissue extract, the British comparative thromboplastin, known formerly as the Manchester comparative reagent, as a reference reagent in a standardization procedure (ACP Broadsheet, in press). The BCT is used to characterize 'home-made' and commercial reagents; (2) the use of a uniform system ofreporting prothrombin results, ie, the British corrected ratio. if the visual line fell outside these confidence limits.
The difference between the 'best straight line' and the calculated line can be assessed by measuring the discrepancy between the two lines at various points. Seven points with the following values on the scale of the local method were used: 1-8, 2-0, 2-2, 2-4, 2-6, 2 8, and 3 0; in addition the vertical distance between the two lines was measured from the points on the calculated line equivalent to 1-8 and 3-0 with the British comparative thromboplastin. The latter two points are the extremes of the therapeutic scale with the Manchester reagent (now the British comparative thromboplastin). At each of these points the discrepancy between the value for the British corrected ratio provided by the calculated line and the line drawn following inspection has been measured.
Results

ANALYSIS OF RETURNS
Of the 15 hospitals in the first group which were sent animal brain three were excluded. One centre was excluded because the British comparative thromboplastin had been incorrectly stored and become inactivated; the two other centres were unable to provide results. Of the 15 hospitals in the group which tested the 'home-made' human brain against the British comparative thromboplastin five were excluded. Four centres were not able to provide data for sufficient patients (two provided data for only 10 patients, one for eight, and one for five); the fifth centre failed to provide values for normals. One hospital which had not been originally included in this group returned a complete set of results whilst the study was in progress and therefore was included.
There was little difference between the 'best straight line' drawn through the points by visual comparison and the calculated line for the majority of the hospitals in both groups. Where the two lines did not coincide, two basic patterns emerged (Figs. I and 2) . The lines either diverged or crossed over from each other, confirming the need to take multiple points in calculating the relationship between the calculated and best line from visual estimation. The Table  indicates realistic in clinical practice than the line obtained by calculation. Drawing a line by visual assessment through points on a graph can be fairly simple if the points fall close to a linear distribution (Fig. 3) . If there are a number of aberrant points the line drawn by visual means can vary considerably (Fig. 4) . We have shown that when the British comparative thromboplastin is compared with human brain and animal brain extracts the line of 'best fit' is sufficiently close to the calculated line. Where discrepancies arise is when a number of 'rogue' or 'aberrant' points occur (Fig. 4) . When drawing the line visually, occasional aberrant points tend to be ignored, in order to produce a line which represents most of the points, whereas the calculation takes these aberrant points into account. This means it is less likely that the lines will coincide.
It is probably sound practice to ignore isolated aberrant points. A considerable number of variables may lead to disagreement between successive tests on coumarin blood samples. Thromboplastin reagents vary in sensitivity to coumarin blood factors, and animal reagents are relatively insensitive to factors VII and X. In the first few days of anticoagulant treatment factor VII may be the principal factor depressed. Although we asked hospitals to exclude patients who had been on anticoagulants for less than 72 hours, occasionally a predominantly factor VII deficiency is present at that time, or even later. In these circumstances the prothrombin ratio with a reagent relatively insensitive to factor VII will be much lower than the expected ratio corresponding to the British comparative thromboplastin and will be an aberrant result. That this has occurred in this study is suggested by the fact that although the 'best line' was drawn without difficulty at all centres using Diagen, more aberrant points were present than at the centres using human brain. In addition, many variables influence prothrombin times and some of these are difficult to trace, to explain an aberrant result. The following have been shown to cause discrepancies between consecutive prothrombin time tests:
(1) An example of this can be seen in Fig. 5 where all the points are distributed on or close to a line with the exception of a single 'rogue' value. It is justifiable to plot the line through the remainder of the points, ignoring the single 'rogue' value; this should only be done where there are one or two outlying values with the remainder of the points closer to the line. Where more than two of the points of the 12 results on coumarin patients returned for the standardization procedure (ACP Broadsheet) are farther than 05 British corrected ratio from the line (in a vertical plane) it is suggested that the procedure be regarded as unsatisfactory, and it should be repeated with a fresh set of specimens. Figure 4 illustrates the results where a repeat of the procedure would be advisable. Unsatisfactory results may be caused by an unfortunate selection of specimens, eg, the inclusion of specimens with predominantly factor VII defects. Faulty technique (see above) will likewise result in aberrant points.
It is, of course more likely that a cluster of results in the higher ratio range will tend to give more rogue values than a similar group at the lower end of the ratio scale. The Committee has guarded against this by recommending that the 12 coumarin plasmas needed for the standardization procedure should fall within the range of 1-7 to 3-8 prothrombin ratio with the British comparative thromboplastin (ACP Broadsheet).
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